Medpace (NASDAQ:MEDP) Cut to Hold at Wall Street Zen
by Doug Wharley · The Cerbat GemWall Street Zen lowered shares of Medpace (NASDAQ:MEDP – Free Report) from a buy rating to a hold rating in a research report released on Saturday.
Several other research firms also recently weighed in on MEDP. Leerink Partners cut their price objective on Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Jefferies Financial Group raised Medpace from a “hold” rating to a “buy” rating and set a $560.00 target price on the stock in a report on Friday, February 13th. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Mizuho set a $582.00 target price on Medpace in a report on Wednesday, February 11th. Finally, Royal Bank Of Canada cut their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $467.08.
Get Our Latest Research Report on Medpace
Medpace Stock Up 2.6%
NASDAQ MEDP opened at $421.37 on Friday. Medpace has a twelve month low of $284.10 and a twelve month high of $628.92. The company has a market cap of $12.03 billion, a price-to-earnings ratio of 26.48, a price-to-earnings-growth ratio of 2.08 and a beta of 1.39. The business’s fifty day moving average is $470.48 and its 200 day moving average is $535.10.
Medpace (NASDAQ:MEDP – Get Free Report) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The company had revenue of $706.60 million for the quarter, compared to the consensus estimate of $697.82 million. During the same quarter last year, the business posted $3.67 EPS. Medpace’s revenue for the quarter was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts anticipate that Medpace will post 17.1 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Medpace news, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 20.50% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently made changes to their positions in MEDP. Quent Capital LLC acquired a new position in shares of Medpace in the 3rd quarter valued at about $25,000. Optiver Holding B.V. acquired a new position in shares of Medpace in the 3rd quarter valued at about $27,000. Geneos Wealth Management Inc. lifted its stake in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the period. Steigerwald Gordon & Koch Inc. acquired a new position in shares of Medpace in the 4th quarter valued at about $30,000. Finally, Elyxium Wealth LLC acquired a new position in shares of Medpace in the 4th quarter valued at about $30,000. 77.98% of the stock is owned by institutional investors and hedge funds.
About Medpace
Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.
Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.